Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study

The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadokostaki, Eleni, Tentolouris, Anastasios, Anastasiou, Ioanna A., Psichogiou, Mina, Iliaki, Evangelia, Eleftheriadou, Ioanna, Hatzakis, Angelos, Tentolouris, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954340/
https://www.ncbi.nlm.nih.gov/pubmed/35335014
http://dx.doi.org/10.3390/vaccines10030382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954340/
https://www.ncbi.nlm.nih.gov/pubmed/35335014
http://dx.doi.org/10.3390/vaccines10030382

Ejemplares similares